BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 19882053)

  • 1. Nucleic acid amplification technology for hepatitis B virus, and its role in blood donation screening in blood banks.
    Bamaga MS; Azahar EI; Al-Ghamdi AK; Alenzi FQ; Farahat FM
    Saudi Med J; 2009 Nov; 30(11):1416-21. PubMed ID: 19882053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations.
    Bamaga MS; Bokhari FF; Aboud AM; Al-Malki M; Alenzi FQ
    Saudi Med J; 2006 Jun; 27(6):781-7. PubMed ID: 16758035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
    Kuhns MC; Kleinman SH; McNamara AL; Rawal B; Glynn S; Busch MP;
    Transfusion; 2004 Sep; 44(9):1332-9. PubMed ID: 15318857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test.
    Kleinman SH; Strong DM; Tegtmeier GG; Holland PV; Gorlin JB; Cousins C; Chiacchierini RP; Pietrelli LA
    Transfusion; 2005 Aug; 45(8):1247-57. PubMed ID: 16078909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value?
    Stramer SL; Zou S; Notari EP; Foster GA; Krysztof DE; Musavi F; Dodd RY
    Transfusion; 2012 Feb; 52(2):440-6. PubMed ID: 21810101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests.
    Schmidt M; Nübling CM; Scheiblauer H; Chudy M; Walch LA; Seifried E; Roth WK; Hourfar MK
    Vox Sang; 2006 Oct; 91(3):237-43. PubMed ID: 16958836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor screening for hepatitis B virus infection in a cell and tissue bank.
    Solves P; Mirabet V; Alvarez M; Vila E; Quiles F; Villalba JV; Montoro JA; Soler MA; Roig RJ
    Transpl Infect Dis; 2008 Dec; 10(6):391-5. PubMed ID: 18665905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of an algorithm for the reentry of volunteer blood donors deferred due to false-positive test results for antibody to hepatitis B core antigen.
    Katz L; Strong DM; Tegtmeier G; Stramer S
    Transfusion; 2008 Nov; 48(11):2315-22. PubMed ID: 18647367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations.
    Bouchardeau F; Girault A; Razer A; Servant-Delmas A; Mercier M; Laperche S
    Transfusion; 2006 Dec; 46(12):2047-52. PubMed ID: 17176315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience.
    O'Brien SF; Fearon MA; Yi QL; Fan W; Scalia V; Muntz IR; Vamvakas EC
    Transfusion; 2007 Oct; 47(10):1809-15. PubMed ID: 17880605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study about seroconversion of HBV NAT screening-positive crowd from blood donors].
    Wang DW; Wang TB; Liu FP; Shi LL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):127-9. PubMed ID: 18574536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.
    Satake M; Taira R; Yugi H; Hino S; Kanemitsu K; Ikeda H; Tadokoro K
    Transfusion; 2007 Jul; 47(7):1197-205. PubMed ID: 17581154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occult hepatitis B virus infection: implications in transfusion.
    Allain JP
    Vox Sang; 2004 Feb; 86(2):83-91. PubMed ID: 15023176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two HBV DNA+/HBsAg- blood donors identified by HBV NAT in Shenzhen, China.
    Shang G; Yan Y; Yang B; Shao C; Wang F; Li Q; Seed CR
    Transfus Apher Sci; 2009 Aug; 41(1):3-7. PubMed ID: 19487161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of antibody to hepatitis B core antigen screening among blood donors in Eastern Saudi Arabia. Need to replace the test by HBV DNA testing.
    Panhotra BR; Al-Bahrani A; Ul-Hassan Z
    Saudi Med J; 2005 Feb; 26(2):270-3. PubMed ID: 15770304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain.
    González R; Torres P; Castro E; Barbolla L; Candotti D; Koppelman M; Zaaijer HL; Lelie N; Allain JP; Echevarría JM
    Transfusion; 2010 Jan; 50(1):221-30. PubMed ID: 19682332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT.
    Brojer E; Grabarczyk P; Liszewski G; Mikulska M; Allain JP; Letowska M;
    Hepatology; 2006 Dec; 44(6):1666-74. PubMed ID: 17133474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult hepatitis B virus infection.
    Allain JP
    Transfus Clin Biol; 2004 Feb; 11(1):18-25. PubMed ID: 14980545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.